Abstract
Hepatocellular carcinoma (HCC) is the fifth most common and third deadliest primary neoplasm. Since HCC is a particularly vascular solid tumor, we determined the antitumor and antiangiogenic activities of sunitinib malate, a potent inhibitor of two receptors involved in angiogenesis – vascular endothelial growth factor receptor (VEGFR) and plateletderived growth factor receptor (PDGFR). In the present study, we reported that treatment of HepG2 and SK-Hep-1 cells with sunitinib led to growth inhibition and apoptosis in a dose-dependent fashion. Sunitinib inhibited phosphorylation of VEGFR-2 at Tyr951 and PDGFR-β at Tyr1021 both in vitro and in vivo. Sunitinib also suppressed tumor growth of five patient-derived xenografts. Sunitinib-induced tumor growth inhibition was associated with increased apoptosis, reduced microvessel density and inhibition of cell proliferation. This study provides a strong rationale for further clinical investigation of sunitinib in patients with hepatocellular carcinoma.
Keywords: Sunitinib, hepatocellular carcinoma, growth inhibition, anti-angiogenesis
Current Cancer Drug Targets
Title: Sunitinib (SUTENT, SU11248) Suppresses Tumor Growth and Induces Apoptosis in Xenograft Models of Human Hepatocellular Carcinoma
Volume: 9 Issue: 6
Author(s): H. Huynh, V. C. Ngo, S. P. Choo, D. Poon, H. N. Koong, C. H. Thng, H. C. Toh, L. Zheng, L. C. Ong, Y. Jin, I. C. Song, A. P.C. Chang, H. S. Ong, A. Y.F. Chung, P. K.H. Chow and K. C. Soo
Affiliation:
Keywords: Sunitinib, hepatocellular carcinoma, growth inhibition, anti-angiogenesis
Abstract: Hepatocellular carcinoma (HCC) is the fifth most common and third deadliest primary neoplasm. Since HCC is a particularly vascular solid tumor, we determined the antitumor and antiangiogenic activities of sunitinib malate, a potent inhibitor of two receptors involved in angiogenesis – vascular endothelial growth factor receptor (VEGFR) and plateletderived growth factor receptor (PDGFR). In the present study, we reported that treatment of HepG2 and SK-Hep-1 cells with sunitinib led to growth inhibition and apoptosis in a dose-dependent fashion. Sunitinib inhibited phosphorylation of VEGFR-2 at Tyr951 and PDGFR-β at Tyr1021 both in vitro and in vivo. Sunitinib also suppressed tumor growth of five patient-derived xenografts. Sunitinib-induced tumor growth inhibition was associated with increased apoptosis, reduced microvessel density and inhibition of cell proliferation. This study provides a strong rationale for further clinical investigation of sunitinib in patients with hepatocellular carcinoma.
Export Options
About this article
Cite this article as:
Huynh H., Ngo C. V., Choo P. S., Poon D., Koong N. H., Thng H. C., Toh C. H., Zheng L., Ong C. L., Jin Y., Song C. I., Chang P.C. A., Ong S. H., Chung Y.F. A., Chow K.H. P. and Soo C. K., Sunitinib (SUTENT, SU11248) Suppresses Tumor Growth and Induces Apoptosis in Xenograft Models of Human Hepatocellular Carcinoma, Current Cancer Drug Targets 2009; 9 (6) . https://dx.doi.org/10.2174/156800909789271530
DOI https://dx.doi.org/10.2174/156800909789271530 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
What are the Cancer Risks in BRCA Carriers Apart from Those Regarding the Breast and the Ovary?
Current Women`s Health Reviews Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery INNO-206 (DOXO-EMCH), an Albumin-Binding Prodrug of Doxorubicin Under Development for Phase II Studies
Current Bioactive Compounds Cancer Stem Cells in Prostate Cancer Chemoresistance
Current Cancer Drug Targets COVID-19: The Significance of Platelets, Mitochondria, Vitamin D, Serotonin and the Gut Microbiota
Current Medicinal Chemistry Non Alcoholic Fatty Liver: Epidemiology and Natural History
Reviews on Recent Clinical Trials Targeting Cancer Cells by an Oxidant-Based Therapy
Current Molecular Pharmacology Basics in Endoscopic Ultrasound Part 1: Diagnostic Indications and Tissue Sampling
Reviews on Recent Clinical Trials Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions
Current Medicinal Chemistry Molecular Targets of FTY720 (Fingolimod)
Current Molecular Medicine Pre-feasibility Study for Establishing Radioisotope and Radiopharmaceutical Production Facilities in Developing Countries
Current Radiopharmaceuticals Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers
Current Medicinal Chemistry Absorption, Pharmacokinetics and Disposition Properties of Solid Lipid Nanoparticles (SLNs)
Current Drug Metabolism Is the Cytoskeleton an Intracellular Receptor for Adrenomedullin and PAMP?
Current Protein & Peptide Science Modulation of Cell Death in Age-Related Diseases
Current Pharmaceutical Design Mitochondria and Familial Predisposition to Breast Cancer
Current Genomics Chitosan Nanoparticles: A Therapeutic Carrier for Delivery of DNA, siRNA and CpG-ODNs
Nanoscience & Nanotechnology-Asia The Potential Role of Carbon Nanoparticles in Lymph Node Tracing, Recurrent Laryngeal Nerve Identification and Parathyroid Preservation During Thyroid Surgery: A Systematic Review
Current Pharmaceutical Design Cellular Targets for Anticancer Strategies
Current Drug Targets Peptide-Receptor Ligands and Multivalent Approach
Anti-Cancer Agents in Medicinal Chemistry